Eventide Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Eventide Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-276,200	Closed	-$1.87M	–	156
2022 Q4	$1.87M	Hold	276,200	–	–	0.04%	134
2022 Q3	$4.01M	Buy	+276,200	New	+$3.86M	0.08%	127
2022 Q1	–	Sell	-138,821	Closed	-$1.84M	–	141
2021 Q4	$1.84M	Sell	138,821 -526,860	-79%	-$8.39M	0.02%	142
2021 Q3	$11.6M	Hold	665,681	–	–	0.15%	120
2021 Q2	$15.9M	Sell	665,681 -707,319	-52%	-$18.5M	0.21%	104
2021 Q1	$35.3M	Sell	1,373,000 -307,000	-18%	-$8.07M	0.52%	70
2020 Q4	$31.9M	Hold	1,680,000	–	–	0.49%	68
2020 Q3	$21.2M	Hold	1,680,000	–	–	0.41%	70
2020 Q2	$20.3M	Hold	1,680,000	–	–	0.44%	69
2020 Q1	$12.9M	Hold	1,680,000	–	–	0.42%	71
2019 Q4	$29.9M	Hold	1,680,000	–	–	0.84%	45
2019 Q3	$19.5M	Buy	1,680,000 +180,000	+12%	+$2.91M	0.64%	57
2019 Q2	$33.2M	Buy	1,500,000 +600,000	+67%	+$14.1M	1.01%	31
2019 Q1	$25.8M	Hold	900,000	–	–	0.89%	38
2018 Q4	$17.8M	Hold	900,000	–	–	0.79%	46
2018 Q3	$19.9M	Hold	900,000	–	–	0.73%	48
2018 Q2	$7.31M	Hold	900,000	–	–	0.3%	85
2018 Q1	$8.53M	Buy	900,000 +191,000	+27%	+$2M	0.4%	69
2017 Q4	$6.91M	Buy	709,000 +313,000	+79%	+$3.26M	0.36%	74
2017 Q3	$2.64M	Buy	396,000 +206,100	+109%	+$1.47M	0.15%	95
2017 Q2	$1.37M	Buy	189,900 +91,800	+94%	+$675K	0.09%	105
2017 Q1	$766K	Buy	+98,100	New	+$737K	0.05%	110

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Eventide Asset Management's KALV Position: Q1 2023 in Review

Eventide Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 276,200 shares — an estimated $1.87M sold.

Eventide Asset Management first reported a position in KALV in Q1 2017 and held it in 22 quarters. The position peaked at $35.3M in Q1 2021. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Eventide Asset Management reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Eventide Asset Management sold 276,200 KalVista Pharmaceuticals shares in Q1 2023, an estimated $1.87M.
Eventide Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2017 and held it in 22 quarters.
Eventide Asset Management's KalVista Pharmaceuticals position peaked at $35.3M in Q1 2021.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Eventide Asset Management's 13F filing for Q1 2023, filed 15 May 2023.